RecruitingNot ApplicableNCT07709416

Toludesvenlafaxine for Non-specific Low Back Pain

Efficacy and Safety of Toludesvenlafaxine in the Treatment of Non-specific Low Back Pain

Sponsor

Beijing Tiantan Hospital

Enrollment

132 participants

Start Date

Jul 15, 2026

Study Type

INTERVENTIONAL

Conditions

Non specific low back pain

Summary

Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug toludesvenlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Active Comparator #1 and a drug called Toludesvenlafaxine for people with non specific low back pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGActive Comparator #1

Participants in the control group will receive routine clinical care for chronic nonspecific low back pain.

DRUGToludesvenlafaxine

Participants in the toludesvenlafaxine group will receive oral toludesvenlafaxine in addition to background care. Toludesvenlafaxine will be administered at 80 mg once daily. For participants with insufficient pain relief and acceptable tolerability, the dose may be cautiously increased to 160 mg once daily. The maintenance treatment period will be 3 months.